The exact mechanism of action of ginkgo biloba is not known. Human pharmacological data show increased EEG vigilance in geriatric subjects, reduction in blood viscosity and improved cerebral perfusion in specific areas in healthy men (60-70 years) and reduction in platelet aggregation. Additionally, vasodilating effects on forearm blood vessels causing increased regional blood flow are shown.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| N06DX02 | Ginkgo folium | N Nervous system → N06 Psychoanaleptics → N06D Anti-dementia drugs → N06DX Other anti-dementia drugs |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| GINKGO BILOBA Film coated tablet | Health Products Regulatory Authority (IE) | MPI, EU: SmPC |
Ginkgo biloba is an active ingredient of these brands:
Brazil (BR)Croatia (HR)Ecuador (EC)France (FR)
Germany (DE)Hong Kong (HK)
Israel (IL)Lithuania (LT)
Romania (RO)
Spain (ES)Tunisia (TN)
Turkey (TR)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
